ATE346605T1 - METHOD FOR TRIGGERING A SUSTAINED IMMUNE RESPONSE - Google Patents

METHOD FOR TRIGGERING A SUSTAINED IMMUNE RESPONSE

Info

Publication number
ATE346605T1
ATE346605T1 AT02746503T AT02746503T ATE346605T1 AT E346605 T1 ATE346605 T1 AT E346605T1 AT 02746503 T AT02746503 T AT 02746503T AT 02746503 T AT02746503 T AT 02746503T AT E346605 T1 ATE346605 T1 AT E346605T1
Authority
AT
Austria
Prior art keywords
enkephalin
triggering
immune response
sustained immune
sustained
Prior art date
Application number
AT02746503T
Other languages
German (de)
Inventor
Nicholas P Plotnikoff
Original Assignee
Nicholas P Plotnikoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas P Plotnikoff filed Critical Nicholas P Plotnikoff
Application granted granted Critical
Publication of ATE346605T1 publication Critical patent/ATE346605T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.
AT02746503T 2001-05-16 2002-05-16 METHOD FOR TRIGGERING A SUSTAINED IMMUNE RESPONSE ATE346605T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29123701P 2001-05-16 2001-05-16

Publications (1)

Publication Number Publication Date
ATE346605T1 true ATE346605T1 (en) 2006-12-15

Family

ID=23119478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02746503T ATE346605T1 (en) 2001-05-16 2002-05-16 METHOD FOR TRIGGERING A SUSTAINED IMMUNE RESPONSE

Country Status (8)

Country Link
US (2) US8633150B2 (en)
EP (1) EP1401474B1 (en)
CN (2) CN1541103A (en)
AT (1) ATE346605T1 (en)
AU (1) AU2002316221A1 (en)
DE (1) DE60216458T2 (en)
RU (1) RU2313364C2 (en)
WO (1) WO2002092018A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1814277A (en) * 2005-12-07 2006-08-09 黄建寅 Use of methionine enkephalin in preparation of medicine for reducing toxic and side effect of chemical or radioactive therapy
RU2010114019A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) MINIGASTRIN AS A THERAPEUTIC MEDICINE
US20100184704A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent
JP5385276B2 (en) * 2007-09-11 2014-01-08 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Therapeutic uses of neuropeptide EI and ACTH7-38 and compositions thereof
US20100204155A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
WO2009043455A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Therapeutic uses of angiogenin 108-122 and gluten exorphin a5
US20100210568A1 (en) * 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
EP2187947A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of calcitonin as anti-angiogenic agent
WO2009033701A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of urodilatin as a therapeutic agent
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP4593639B2 (en) 2008-03-04 2010-12-08 株式会社マルハニチロ食品 Peptide-containing feeding regulator
US8785484B2 (en) * 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
WO2013042811A1 (en) * 2011-09-22 2013-03-28 (주)바이오에프디엔씨 Caffeoyl alpha neoendorphin peptide derivative and use thereof as an anti-itch and anti-atopic material
US9937146B2 (en) 2016-03-23 2018-04-10 Bioadatp, Llc Enkephalin-influencing composition and method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
DK1302468T3 (en) * 1992-12-29 2009-03-02 Abbott Lab Methods and intermediates for the preparation of compounds that inhibit retroviral protease
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins

Also Published As

Publication number Publication date
RU2003136161A (en) 2005-03-10
EP1401474A4 (en) 2005-05-11
EP1401474B1 (en) 2006-11-29
RU2313364C2 (en) 2007-12-27
WO2002092018A2 (en) 2002-11-21
DE60216458T2 (en) 2007-09-27
WO2002092018A3 (en) 2003-12-11
AU2002316221A1 (en) 2002-11-25
US8633150B2 (en) 2014-01-21
CN101417120A (en) 2009-04-29
EP1401474A2 (en) 2004-03-31
CN1541103A (en) 2004-10-27
US20140024588A1 (en) 2014-01-23
US20030148942A1 (en) 2003-08-07
DE60216458D1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE346605T1 (en) METHOD FOR TRIGGERING A SUSTAINED IMMUNE RESPONSE
CY1113253T1 (en) Dosage regimen for therapeutic treatment of a traumatic brain injury with progesterone
CY1119389T1 (en) METHOD FOR THE TREATMENT OF TREATMENT OF MULTIPLE SCIENCE
AR047229A1 (en) ADMINISTRATION OF POLYMERIC CONJUGATES OF PEPTIDES AND THERAPEUTIC PROTEINS BY MEANS OF COVERED MICROPROJECTIONS
MX2009013574A (en) Modified release solid or semi-solid dosage forms.
EA200702522A1 (en) SYSTEM OF DELIVERY OF MEDICINES IN THE CAVITY OF THE MOUTH AND METHODS OF ITS APPLICATION
EA201591701A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
ATE292453T1 (en) ANTIVIRAL DRUG
EE200200565A (en) Combination therapy with vascular adverse effects
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.
WO2007079195A3 (en) Gastric retentive gabapentin dosage forms and methods for using same
DE69812100T2 (en) MEDICINAL PRODUCT CONTAINING ADENOSINE
ATE413187T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INTERFERON TAU
AR023185A1 (en) CANCER TREATMENT IMPROVED WITH TEMOZOLOMIDE
ATE421882T1 (en) QUICK DISSOLVING AZITHROMYCIN IN SINGLE DOSE FORM
EE200200549A (en) Split dose therapy with vascular damaging activity
FR2839450B1 (en) MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
DE60028207D1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF CALCIUM ANTAGONISTS
DE60125377D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN
BRPI0705943A2 (en) oral dosage formulations of protease resistant polypeptides and their uses for treatment
UA2972U (en) METHOD OF TREATMENT OF INITIAL MANIFESTATIONS OF MULTIPLE SCLEROSIS
RU2007120403A (en) METHOD FOR LOCAL THERAPY OF AUTOIMMUNE ARTHRITIS
MX2018010367A (en) Titration of cebranopadol.
ECSP003771A (en) METHOD TO PREVENT DIARRHEA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties